News & Resources
Imaging - Advancing Biomarker Research for Alzheimer’s Disease Diagnosis
Imaging: Advancing Biomarker Research for Alzheimer's Disease Diagnosis Alzheimer's disease (AD) presents a significant challenge, not only for those diagnosed but also for their families and healthcare providers. As the global population ages, the urgency for effective diagnostic tools and treatment strategies intensifies.
Half-year Trading update - FY2025
16 April 2025: IXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering intelligent insights in neuroscience, today provides a trading update ahead of its interim results for the six months ended 31 March 2025.
Discussing research multi-biomarker advances in Alzheimer’s Disease at ADPD 2025
This week we will be at the ADPD 2025 International Conference talking about some of our latest biomarker research. Specifically, we are presenting an AI-based approach to differentiate different types of dementia from magnetic resonance imaging (MRI).
Huntington's Disease: Your Imaging Analysis & Operations Solutions Partner
Transforming clinical research in Huntington’s diseaseEstablished for over 20 years, IXICO is the leading provider of neuroimaging services for Huntington’s disease (HD) clinical trials. Our mission is to advance investigational therapies through innovative imaging solutions that comply with global regulatory standards.
Your Imaging Analysis & Operations Experts in Alzheimer’s Disease Clinical Research
IXICO’s Alzheimer’s Disease Footprint at a GlancePioneering Precision in AD Imaging IXICO excels in AD imaging with advanced imaging biomarkers to quantify markers such as amyloid plaques, tau tangles, and brain atrophy. Our AI-driven IXIQ. Ai platform enhances the accuracy and efficiency of brain imagine measurements.
Executing a Multi-Arm Phase 1 Alzheimer’s Disease Global Clinical Trial with Clinilabs and IXICO
In the realm of Central Nervous System (CNS) clinical trials, the expertise in science and technology is constantly being pushed to new boundaries.
Comparison of two natural history studies as part of the HD-IH consortium: a use case for historical external control group matching in clinical trials
External control groups can support regulatory decision-making in clinical trials, especially rare diseases. In Huntington’s disease (HD) there is a wealth of historical data, but matching historical data to clinical trials is challenging.
1-8 of 156 results